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AbstrACt
Purpose To establish a cohort that enables identification 
of genomic factors that influence human health and 
empower increased blood donor health and safe blood 
transfusions. Human health is complex and involves 
several factors, a major one being the genomic aspect. The 
genomic era has resulted in many consortia encompassing 
large samples sizes, which has proven successful for 
identifying genetic factors associated with specific traits. 
However, it remains a big challenge to establish large 
cohorts that facilitate studies of the interaction between 
genetic factors, environmental and life-style factors as 
these change over the course of life. A major obstacle to 
such endeavours is that it is difficult to revisit participants 
to retrieve additional information and obtain longitudinal, 
consecutive measurements.
Participants Blood donors (n=110 000) have given 
consent to participate in the Danish Blood Donor Study. 
The study uses the infrastructure of the Danish blood 
banks.
Findings to date The cohort comprises extensive 
phenotype data and whole genome genotyping data. 
Further, it is possible to retrieve additional phenotype data 
from national registries as well as from the donors at 
future visits, including consecutive measurements.
Future plans To provide new knowledge on factors 
influencing our health and thus provide a platform for 
studying the influence of genomic factors on human 
health, in particular the interaction between environmental 
and genetic factors.
IntroduCtIon
A person's health is determined by complex 
interactions between genetic, environmental 
and lifestyle factors. Analysing these factors 
collectively and prospectively is preferable. 
However, this is usually only possible using 
birth-cohorts and large population-based 
cohorts, and due to the extensive effort 
involved in establishing such cohorts, they 
are rare. The Danish Blood Donor Study 
(DBDS;  dbds. dk) is a large prospective cohort 
of blood donors aiming at identifying predic-
tors of healthy donors. As part of this cohort, 
we have now established DBDS Genomic 
Cohort assessing common single nucleotide 
polymorphisms (SNPs) in 110 000 donors. 
Thus, the DBDS Genomic Cohort provides 
a comprehensive catalogue for large-scale 
genetic analyses in relation to numerous 
environmental and lifestyle factors affecting 
donor’s health. A description of summary 
statistics on phenotypes and data coverage 
is provided in table 1. A detailed sociodemo-
graphic description of Danish blood donors, 
including sex and age distribution, ethnicity, 
education, employment and level of urbanisa-
tion is found in Burgdorf et al (2017).1 
The evaluation of blood donor’s health is 
important for several reasons. It is crucial for 
both the donor and the blood recipient that 
a healthy donor population is maintained 
strengths and limitations of this study
 ► Cohort design allows for consequative 
meassurements.
 ► Diesase status is continuously reassesset.
 ► The cohort consist of select population of blood 
donors.
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with a high donation rate and a low dropout rate, thereby 
ensuring a steady blood supply. Evidence-based guide-
lines for donor recruitment, care and retention are 
needed to ensure that donor recruitment can focus on 
individuals who are likely to remain healthy and donate 
frequently in the long term. One obvious relevant influ-
ential parameter relates to iron metabolism: we know that 
hundreds of genes impact the generation and regulation 
of blood cells2 and also influence phenotype variations 
of iron absorption and metabolism.3–5 Genome-wide SNP 
information is expected to provide knowledge enabling 
us to evaluate to whom donating blood will be unprob-
lematic, thus facilitating retention of a stable blood donor 
population. Another parameter is altruism. Altruism as 
part of a prosocial behaviour, the selfless concern for the 
welfare of others,6 is generally considered a typical blood 
donor characteristic.7 However, altruism in the context of 
voluntary blood donation has also been shown to be a 
very complex phenotype.7 In a previous study, we found 
a substantially larger genetic influence on blood donor 
behaviour compared with most previous twin studies on 
altruism, which further highlights the heterogeneity of 
the blood donor personality.8 The considerable amount 
of kinship (twins and siblings) in the cohort in combi-
nation with socioeconomic variables from the Danish 
registries will enable us to further differentiate between 
genetic impact and social basis of altruism in blood dona-
tion. The genome-wide SNP information will provide 
knowledge that can aid in the identification of long-
term and steady donors. Further, we will test for associa-
tion between genotype SNP information and prodromal 
symptoms of somatic and psychiatric disease or illnesses.
The DBDS Genomic Cohort offers the possibility to 
assess the impact of heterogeneous exposures in a broad 
range of phenotypes, such as mental state, risk-taking 
behaviour and characterisation of blood components 
and immune defense. The setup of the study allows for 
researchers to assess the genetic association in (1) cross 
sectional studies to investigate, that is, the variation 
of phenotypic characteristic, clinical and biochemical 
measurements, (2) retrospective studies of, for example, 
rehabilitation capacity and (3) prospective studies, for 
example, analysing the variation of phenotypes and clin-
ical measurements over time and even identify prodromal 
symptoms.
Cohort desCrIPtIon
Population
The nation-wide blood donor population in Denmark 
consists of more than 230 000 donors giving more than 
300 000 blood donations annually (http://www. blod-
donor. dk). Blood donation in Denmark is voluntary and 
unpaid. This means that the donation is based on the 
desire to help others, who need it and not the desire of an 
economic benefit. Blood donors must be physically well, 
aged 17 and 67 years, and weigh more than 50 kilos. Indi-
viduals in chronic medical treatment or frequent travel-
lers to countries with high prevalence of blood disease are 
not allowed to participate. The deferral rules can be seen 
at http://www. bloddonor. dk. Blood donors from foreign 
countries must have lived in Denmark for a minimum 
of 1 year, have a Danish social security number and have 
learnt the Danish language to prevent misunderstandings 
between the donor and the blood bank professionals.
The nationwide Danish blood bank is an integrated 
part of the Danish healthcare system financed by local 
and state taxes. The Danish healthcare system is adminis-
trated by democratically elected assemblies from national 
state institutions, regions and municipalities. The Danish 
blood banks are non-profit organisations owned and 
operated by each of the five regions in Denmark. The 
blood banks have a national board to structure collabora-
tion across regions on recruiting donors, processing and 
distributing the blood for the Danish population. The 
DBDS is building on the structured Danish blood bank 
system in the regions responsible for administering dona-
tion sites at 27 hospitals in addition to five mobile dona-
tion units using 180 selected sites nationally (eg, large 
companies, sports centres and universities)
At the blood donation centres and attached laboratories, 
the entire necessary infrastructure needed for the collec-
tion of biological samples and structured data is in place. 
Both blood plasma and whole blood for DNA extraction 
are available from all donors. The blood bank infra-
structure already has laboratory facilities with educated 
staff (nurses, technicians, IT specialists and physicians). 
In addition, the blood bank professionals facilitate the 
testing of the blood for a variety of biomarkers and holds 
expertise in large scale storage of biological material.
Contact to participants at the blood banks is funda-
mental to our study. Blood donors are asked to partici-
pate and sign an informed consent when they visit the 
blood bank to donate blood. This consent allows us to use 
Table 1 Prevalence and missingness of environmental 
variables
Participants
Missingness
 (%)
Men 48.8% 0
Women 51.2% 0
Age* 41 (29–50)* 0
Height (cm)* 175.6 (169–182) 0.53
Weight (kg)* 78.1 (67–87) 0.82
BMI 25.3 (22–27) 1.2
Smoking 11.9% 1.3
Alcohol consumption 
(daily)
3.0% 4.7
Questionnaire 1 87 000
Questionnaire 2 50 000
*Mean (Quartiles).
BMI, body mass index.
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the blood samples from their past and future donations 
to study the impact of genetic and immunological factors 
on current and future health and disease. The inclusion 
and exclusion criteria for blood donation and participa-
tion in DBDS are the same with 95% of the blood donors 
who are invited agrees to participate in DBDS.9
Questionnaires
From March 2010 until July 2015, all participating donors 
had to complete a four-page paper-based questionnaire 
with questions of self-experienced physical and mental 
health including the 12-item short form (SF-12) stan-
dardised health survey, smoking habits, alcohol intake, 
exercise, food intake, supplemental iron intake, height, 
weight and waist circumference. Total 85 000 individ-
uals filled out the paper questionnaire. As a follow-up 
to the initial paper-based questionnaire, we have devel-
oped and implemented a digital and flexible tablet-
based questionnaire platform, using the open source 
survey software tool LimeSurvey.10 This enables a rapid, 
easy and cost-effective procedure to collect self-reported 
data on health traits from the participating donors at 
the donor sites at multiple time-points. The first digital 
questionnaire was implemented and used from July 
2015 until May 2018. The questionnaire focused on the 
following research questions: allergy, ADHD, migraine, 
hidradenitis, depression and Restless Legs Syndrome. It 
also contains questions from the paper-based question-
naire: SF-12, smoking habits, alcohol intake, height and 
weight. In total, 48 000 DBDS participants completed 
the first digital questionnaire. The second digital ques-
tionnaire started in June 2018. It includes questions on: 
sleep patterns, anxiety, migraine, stress, skin diseases, 
endometriosis, pain, learning difficulties, SF-12, smoking 
habits, alcohol intake, height and weight. Using the ques-
tionnaire data, several studies have already assessed the 
factors describing the general health of blood donors, for 
example, hidradentis,11 risk of infection,12 migraine, rest-
less legs and depression.13 14 Also, by revisiting samples, it 
has been possible to assess whether infections correlates 
with obesity15 and how iron deficiency and haemoglobin 
levels affect donor health in general.16 17
registry-based data
There is and has always been equal access to the health-
care system in Denmark; hence, the centralised national 
civil and health registries are unbiased and comprehen-
sive resources of healthcare data. The registries include 
the National Patient Registry containing all hospital-reg-
istered diagnoses since 197518 as well as other specialised 
registries, for example, the Danish Medical Birth Register, 
the Danish Register of Causes of Death and Statistics 
Denmark monitoring, for example, socioeconomic data. 
We have already used the DBDS cohort in epidemio-
logical studies assessing, for example, the mortality19 of 
donors and the effect of blood donation on offspring 
birth weight.20
dbds organisation
The DBDS itself is described in detail by Pedersen et al.9 
Briefly, DBDS is governed by a steering committee with 
a scientific advisory board. All projects are managed by 
the DBDS steering committee. Genetic projects involving 
genetic data in DBDS are run in collaboration between 
DBDS Genomic Consortium that consists of the DBDS 
steering committee, deCODE Genetics and scientific 
collaborators.
Genotyping: DNA is purified from whole blood and 
subsequent stored at −20°C. All samples are then geno-
typed in two batches at deCODE genetics using the Global 
Screening Array by Illumina (batch 1, n=85 000 and batch 
2, n=25 000). The array has a very rich up-to-date content 
of >650 000 SNPs with custom chip content optimised for 
comparison with the Illumina Omni Express chip. All 
genotype data are processed simultaneously for geno-
type calling, quality control and imputation. Initially, 
individuals or SNPs with more than 10% missing data are 
excluded, as are individuals deviating more than three SD 
from the population heterozygosity (correcting for indi-
viduals carrying large copy number variations (CNVs) 
(>100 Kbp)).
Imputation
The genotyping data are imputed using a reference panel 
backbone consisting of (1) UK 1 KG phase 3 and HapMap 
reference to predict non-genotyped SNPs with minor 
allele frequency (MAF)>1% and (2) an in-house dataset 
consisting of n>6000 Danish whole genome sequences to 
improve the prediction of variations with a MAF down 
to around 0.01%.21 Variants listed in the American 
College of Medical Genetics and Genomics guidelines 
are currently not predicted, due to restrictions from the 
Danish National Ethics Committee.22 For future collabo-
rative studies, the Ethics Committee will approve analysis 
of these variants on a case by case basis.
Copy number variations
Using the genotype of b-allele count and log Ratio, CNVs 
are called using pennCNV.23 CNVs called using <20 SNPs 
are excluded and the remaining CNVs are visually 
inspected to exclude false positives.
Statistical design
All data are stored and analysed on a specialised, secure 
section of the 16 000 core Danish National Supercom-
puter for Life Sciences—Computerome (http://www. 
computerome. dtu. dk). Data storage and computational 
analysis is performed on a protected, private cloud envi-
ronment. The analysis environment is capable of dynamic 
scaling and has been successfully tested in a composition 
of over 100 servers totalling more than 300 CPUs, over 
13 TB of RAM and has access to up to 5.7 PB (5700 TB) 
of disk space. The cluster comes with a preconfigured 
queuing system, possibility to run Virtual Machines and 
containers (eg, Docker, Singularity), a set of over 900 
preinstalled tools and packages and a possibility to add 
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GPU servers optimised for Machine Learning and special-
ised big memory systems (1– 8 TB of RAM).
For each hypothesis tested, a synopsis is provided 
including a detailed analysis plan. Information on each 
synopsis will be published either as link to published arti-
cles describing the results or as summary statistic on the 
study website:  http://www. dbds. dk.
Samples
During each visit to a blood donor facility (up to four 
times per year for whole blood donors or up to ten times 
if plasma donors), every participant donates one EDTA 
plasma sample. At inclusion in DBDS one whole blood 
sample is also taken. Plasma samples taken prior to the 
inclusion date are stored for quality assessments and 
will also be accessible for future analyses. All samples 
are frozen within 6 hours of donation and stored in the 
primary collection tubes until processing.
Routine blood measurements including, for example, 
blood group, red and white blood cell counts, haemo-
globin concentration and haematocrit are obtained 
at each donation. Besides routine measures, proj-
ect-related measurements are available, for example, 
subgroups of patients are assessed for ferritin levels, 
infection status (Cytomegalovirus, Toxoplasma gondii and 
Herpes Simplex Virus), HLA-typing and other selected 
markers of infection (circulating cytokines, C reactive 
protein and so on).
General data protection and ethical issues and principles
DBDS has secured necessary permissions and approval 
from the Danish Data Protection Agency (2007-58-
0015) and the Scientific Ethical Committee system 
(M-20090237). New projects within the DBDS Genomic 
consortium will require additional approval by the 
National Committee on Health Research Ethics. DBDS 
will be responsible for the continued contact with, and 
securing future permissions from, relevant Danish author-
ities regarding research on DBDS samples.
Patient and public involvement
Patients and public were not involved in the design of this 
study.
Data availability statement
The study will adhere to the FAIR (http:// datafairport. 
org/: Findable, Accessible, Interoperable and Reusable) 
concepts. Within this legal framework, DBDS Genomic 
Consortium Board can thus decide how and under which 
conditions the data can be shared. Generally, relevant 
summary data will be publicly available via reposito-
ries 3 months after acceptance for publication (H2020 
open-access policy).
FIndIngs to dAte
Initial quality measures that have been assessed:
Kinship
As described, giving blood often runs in families and the 
heritability has been estimated to be >53%.8 It is clear 
from the estimated kinship based on the first batch of 
participants (n=85 000) (figure 1, table 2), that there is 
a considerable first, second and third degree relatives 
among the participants in the DBDS Genomic Cohort.
ethnicity
Based on ~15K overlapping SNPs from the genotyped 
data and the 1000 Genomes samples, we confirm the 
expected population structure of the DBDS cohort; 
most participants are of European ancestry (99%) and 
the following two ethnicity groups are of South Asian 
(0.4%) and East Asian (0.2%) ancestry, respectively. The 
proportion of participants with recent African ancestry is 
Figure 1 Relationships for DBDS donors genotyped as 
part of the first batch(n=85 000). Each point represents a pair 
of related individuals and the colours indicate the degree 
of relatedness (‘InfType’ in KING IBD segment inference): 
monozygotic twins and technical duplicates (MZ/DUP) 
in pink (in the upper left corner), first degree relatives as 
parent-offspring pairs (PO, dark green) and full siblings (FS, 
light green), second and third degree relatives in dark and 
light purple, respectively. The y-axis shows the estimated 
kinship coefficient, defined as the probability that two alleles 
sampled at random (one from each individual) are identical 
by descent. The x-axis shows the proportion of zero identity-
by-state (IBS0), defined as the proportion of SNPs at which 
two samples share no alleles. KING’s criteria were used to 
estimate the degree of relatedness (--related command in 
KING). We used a set of independent high-quality markers 
(excluding palindromic and non-autosomal markers, markers 
with MAF<1%, low call-rate (<99%) and markers in regions 
with high Linkage Disequilibrium) for the relatedness 
calculation. DBDS, The Danish Blood Donor Study; MAF,  
minor allele frequency. 
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extremely low (0.002%) which is expected given the strict 
donor travel quarantine rules. Ethnicity was evaluated 
using FlashPCA2.24
Minor allele frequencies
The distribution of the MAF shows that majority of 
SNPs (84%) are above 1% (figure 2) as expected, which 
provides solid basis for genotype imputation.
strength And lIMItAtIons
Consecutive measurements
A unique feature of this large blood donor cohort is the 
ability to do consecutive assessments. In standard settings, 
participants are typically recruited at a baseline time-point 
and are invited for follow-up studies once or twice in the 
following years. The blood bank represents an advantage 
because most donors have a long-term committed rela-
tionship for blood donation and are seen one to four 
times annually.25 It is therefore possible to collect several 
yearly and consecutive biological samples and question-
naire information over decades for a large number of 
participants. Again, subgroups and samples from specific 
time-points can be used in a retrospective manner.
national-based registries
Denmark has several comprehensive national registries, 
which include both health information and sociodemo-
graphical measures on an individual level. The informed 
consent allows for combining information obtained from 
the DBDS participants and the national registries; the 
Danish National Patient Registry (since 1977), the Danish 
Cancer (since 1943) and Diabetes Registries (since 1992–
2012), the Danish Registry of Medicinal Product Statis-
tics (since 1994), the Civil Registration Registry (since 
1968 vital status, number of children, birthplace, address, 
relocation and more), the Integrated Database for Labor 
Market Research (since 1982, eg, educational level, occu-
pation status, income, social status and other related 
parameters). This facilitates retrospective, cross-sectional 
or prospective studies using registry-based measurements 
in combination with questionnaire-derived data.
donor selection
Although DBDS participants resemble the Danish popu-
lation, a few limitations in the study design may affect the 
generalisability of the results.1 The blood donor exclu-
sion criteria dismiss individuals with infections or diseases 
that are transmittable through blood, weight below 50 kg, 
haemoglobin (Hb) levels below 12.9 g/L in males and 
12.0 g/L in females and curious behaviours: individuals 
with high travel rates to countries with high risk of hepa-
titis and HIV, men who have sex with men, individuals 
who have previously worked as sex workers, those who 
have used intravenous substances and pregnant women. 
Comparing sociodemographical parameters of blood 
donors with that of the total Danish population, we know 
that very low-income and high-income individuals are 
underrepresented among blood donors.1 In this respect, 
we acknowledge that DBDS lacks coverage of certain 
parts of the general population in contrast to traditional 
population-based studies. Similarly, the population based 
UK Biobank study have also reported a ‘healthy volun-
teer’ bias.26
dIsCussIon
The extension of the DBDS with a genomic cohort will 
profoundly impact the usability and empower studies on 
genetic, environmental and lifestyle factors that influence 
blood donor health. Furthermore, the study provides a 
unique platform that facilitates analysis of common 
phenotypes not otherwise found in the national health 
registries, disease resilience factors and interactions 
between genes and environment. Finally, such a large 
healthy cohort holds a huge potential for providing crucial 
information for future precision medicine initiatives and 
similar efforts have been started, for example, ‘All of US’ 
(by NIH, US). In Denmark, we have the advantage of 
a collection of extensive, national health registries that 
Table 2 Related pairs (third degree or closer) for batch 1 DBDS donors genotyped (n=85 000)
Relationship Monozygotic twins Parent-offspring Full siblings Second degree Third degree
Pairs 51 4246 3309 4375 11 433
DBDS, The Danish Blood Donor Study.
Figure 2 MAF distribution of the genotyped SNPs prior 
to quality control. DBDS, The Danish Blood Donor Study; 
MAF, minor allele frequency; SNP, single nucleotide 
polymorphism.
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facilitate epidemiological studies on specific diseases/
outcomes in such a large cohort. For phenotypes and 
symptoms not monitored systematically in these health 
registries, for example, lifestyle factors such as smoking 
habits, sleep patterns and self-perceived health, large 
epidemiological studies are needed but typically difficult 
to conduct. The DBDS Genomic Cohort can facilitate 
such studies. As described above, the DBDS Genomic 
Cohort exploits an existing blood donor platform with 
an extremely high participation rate (>95%), which facili-
tates a straightforward evaluation of donor health in large 
epidemiological studies. Furthermore, the electronic 
questionnaire platform allows for easy and fast imple-
mentation of new, targeted investigations in subgroups 
of the donor population. Together with outcomes from 
the Danish health registries and the millions of retrospec-
tive plasma samples stored in easily accessible freezers, 
DBDS represents a solid phenotyping platform that can 
be used for both cross-sectional epidemiological studies 
and for retrospective biomarker studies. We believe that 
these strengths make the DBDS Genomic Cohort a strong 
competitive player in the field of precision medicine.
The DBDS Genomic Cohort allows us to study gene-en-
vironment interaction that are otherwise difficult to study: 
testing disease development hypotheses, for example, (1) 
cognitive performance in interaction with genetic factors 
and the risk of dementia and (2) determining the contri-
bution of genetic and environmental factors to a pheno-
type such as sleep pattern. One way to study this is by using 
multivariate regression models. As an example, Fan et al 
have recently portrayed an advanced example of gene-en-
vironment interaction analysis incorporating temporal 
and spatial considerations,27 an analysis based on data 
from the Danish civil registries. The DBDS Genomic 
Cohort is particularly valuable for studying disease resis-
tance in individuals exposed to one or more known disease 
risk factors and yet do not proceed to develop the disease. 
One such example could be participants carrying a high 
load of a highly inheritable trait like psychiatric illness in 
the family or known genetic risk factors, who do not have 
psychiatric illness themselves. Last, DBDS also provides 
sequential storage of plasma samples, which allows for 
sequential blood measurements. Such measurements 
could be used to investigate health markers like suPAR 
(soluble urokinase plasminogen activating receptor) and 
the variation associated with the donor’s general health.28
In short, the DBDS Genomic Cohort facilitates the 
investigation of the impact of genomic factors on health 
traits and states.
Integrative analysis of different ‘omics, that is, multio-
mics analysis will be possible in the large DBDS Genomic 
Cohort, which adds tremendously to its value as a resource 
for studying the health of blood donors and correlation 
between blood related traits and states. We expect that 
the DBDS Genomic Cohort will contribute to discovery 
and validation of prodromal symptoms and biomarkers 
of disease, thus providing a better understanding of the 
disease pathologies and suggesting new drug targets.
CollAborAtIon
We encourage scientific collaborations using the data 
generated in the DBDS Genetic Consortium. Published 
summarised data are available on request. Otherwise 
request of data necessitates first approval by the DBDS 
steering committee and if the request is considered 
outside the aim of DBDS, application to the national 
scientific ethical committee is obligatory. Additionally, 
material transfer and data protection agreement need to 
be acquired. Please visit http://www. dbds. dk.
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